BIOR
Income statement / Annual
Last year (2023), Biora Therapeutics, Inc.'s total revenue was $4.00 K,
a decrease of 98.69% from the previous year.
In 2023, Biora Therapeutics, Inc.'s net income was -$124.12 M.
See Biora Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$4.00 K |
$305.00 K |
$1.25 M |
$74.31 M |
$143.99 M |
$127.97 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$93.43 M
|
$100.49 M
|
$92.08 M
|
| Gross Profit |
$4.00 K
|
$305.00 K
|
$1.25 M
|
-$19.12 M
|
$43.49 M
|
$35.90 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
-0.26
|
0.3
|
0.28
|
| Research and Development Expenses |
$29.84 M
|
$24.05 M
|
$45.79 M
|
$47.74 M
|
$63.40 M
|
$48.71 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$68.54 M
|
$75.44 M
|
$61.32 M
|
$51.24 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$4.76 M
|
$5.95 M
|
$58.89 M
|
$50.19 M
|
| Selling, General & Administrative Expenses |
$37.31 M
|
$38.04 M
|
$73.30 M
|
$128.33 M
|
$120.21 M
|
$101.43 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$67.15 M
|
$62.09 M
|
$119.08 M
|
$176.07 M
|
$183.61 M
|
$150.14 M
|
| Cost And Expenses |
$67.15 M
|
$62.09 M
|
$119.08 M
|
$269.50 M
|
$284.10 M
|
$242.21 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$575.00 K
|
$1.80 M
|
| Interest Expense |
$9.82 M
|
$10.99 M
|
$12.64 M
|
$9.92 M
|
$9.20 M
|
$9.09 M
|
| Depreciation & Amortization |
$555.00 K
|
$907.00 K
|
$1.44 M
|
$1.44 M
|
$4.60 M
|
$4.60 M
|
| EBITDA |
-$114.05 M |
-$37.35 M |
-$164.57 M |
-$106.18 M |
-$135.44 M |
-$110.17 M |
| EBITDA Ratio |
-28513.5
|
-122.47
|
-131.97
|
-1.43
|
-0.94
|
-0.86
|
| Operating Income Ratio |
-16785.75
|
-202.56
|
-94.5
|
-1.45
|
-0.97
|
-0.89
|
| Total Other Income/Expenses Net |
-$57.28 M
|
$12.53 M
|
-$60.80 M
|
-$35.00 M
|
-$8.62 M
|
-$9.62 M
|
| Income Before Tax |
-$124.42 M
|
-$49.25 M
|
-$178.64 M
|
-$142.62 M
|
-$148.74 M
|
-$123.86 M
|
| Income Before Tax Ratio |
-31106
|
-161.48
|
-143.26
|
-1.92
|
-1.03
|
-0.97
|
| Income Tax Expense |
-$90.00 K
|
-$420.00 K
|
-$119.00 K
|
-$37.53 M
|
-$706.00 K
|
$5.25 M
|
| Net Income |
-$124.12 M
|
-$38.16 M
|
-$178.52 M
|
-$192.53 M
|
-$148.04 M
|
-$129.11 M
|
| Net Income Ratio |
-31028.75
|
-125.1
|
-143.16
|
-2.59
|
-1.03
|
-1.01
|
| EPS |
-78.7 |
-6.4 |
-46.42 |
-86.3 |
-80.17 |
-119.71 |
| EPS Diluted |
-78.7 |
-6.4 |
-46.42 |
-86.3 |
-80.17 |
-119.71 |
| Weighted Average Shares Out |
$1.58 M
|
$7.64 M
|
$3.85 M
|
$2.23 M
|
$1.85 M
|
$1.08 M
|
| Weighted Average Shares Out Diluted |
$1.58 M
|
$7.64 M
|
$3.85 M
|
$2.23 M
|
$1.85 M
|
$1.08 M
|
| Link |
|
|
|
|
|
|
